Fedratinib – Uses, Dosage, Side Effects, Interaction Fedratinib is an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets bind to and inhibit the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation. Fedratinib is an oral selective inhibitor of Janus-associated kinase 2 (JAK-2) and FMS-like tyrosine kinase 3 (FLT3) that is used in the therapy of intermediate or high-risk, primary or secondary myelofibrosis. Fedratinib has been associated with a high rate of serum enzyme elevations during therapy but has been associated with only rare instances of clinically apparent acute liver injury. Fedratinib Hydrochloride is the monohydrate dihydrochloride salt form of fedratinib, an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets bind to, and inhibit the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation. Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high-risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. Mechanism of Action Fedratinib is an inhibitor of Janus Activated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3. JAK2 is highly active in myeloproliferative neoplasms like myelofibrosis. Fedratinib’s inhibition of JAK2 inhibits phosphorylation of signal transducer and activator of transcription (STAT) 3 and 5, which prevents cell division and induces apoptosis. Fedratinib is a kinase inhibitor that inhibits cell division and induces apoptosis. Patients taking fedratinib may experience anemia, thrombocytopenia, gastrointestinal toxicity, hepatic toxicity, or elevated amylase and lipase. These effects should be managed by reducing the dose, temporarily stopping the medication, or providing transfusions on a case-by-case basis. Fedratinib acts as a competitive inhibitor of protein kinase JAK-2 with IC50=6 nM; related kinases FLT3 and RET are also sensitive, with IC50=25 nM and IC50=17 nM, respectively. Significantly less activity was observed against other tyrosine kinases including JAK3 (IC50=169 nM). In treated cells, the inhibitor blocks downstream cellular signaling (JAK-STAT) leading to the suppression of proliferation and induction of apoptosis. Indications Fedratinib is indicated to treat adults with primary or secondary myelofibrosis that is either intermediate-2 or high-risk. Arabic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. Fedratinib is an oral selective inhibitor of Janus-associated kinase 2 (JAK-2) and FMS-like tyrosine kinase 3 (FLT3) that is used in the therapy of intermediate or high-risk, primary or secondary myelofibrosis Fedratinib hydrochloride is approved for use in adults to treat: Myelofibrosis (a bone marrow disease) that is an intermediate-2 risk or high risk, including the following types: Primary myelofibrosis. Post-polycythemia vera myelofibrosis. Post-essential thrombocythemia myelofibrosis. Fedratinib hydrochloride is also being studied in the treatment of other conditions. For the treatment of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) In the United States, fedratinib is indicated for the treatment of adults with intermediate-2 or high-risk primary or secondary (following polycythemia vera or essential thrombocythemia) myelofibrosis. Primary Myelofibrosis (PMF) Secondary Myelofibrosis Use in Cancer Toremifene is approved to treat: Breast cancer that has metastasized (spread to other parts of the body). It is used in postmenopausal women whose cancer is estrogen receptor-positive (ER+) or when it is not known if the cancer is ER+ or estrogen receptor-negative (ER-). Contraindications A High Alanine Transaminase Level A High Aspartate Transaminase Level Low Amount Of Sodium In The Blood Decreased Blood Platelets A Type Of Brain Function Problem Called Encephalopathy High Blood Pressure A Low Supply Of Oxygen Rich Blood To The Heart Heart Failure High Blood Levels Of The Lipase Enzyme High Blood Levels Of The Amylase Enzyme Difficult Or Painful Urination Wernicke’s Encephalopathy Dosage Strengths: 100 mg Myelofibrosis For patients with a baseline platelet count of 50 x 109/L or greater: 400 mg orally once a day Management of thiamine levels and Wernicke’s encephalopathy (WE): Assess thiamine levels and nutritional status prior to starting therapy, periodically during therapy, and as indicated. Do not initiate this drug in patients with thiamine deficiency; replete thiamine prior to therapy initiation and during therapy if thiamine levels are low. If Wernicke’s encephalopathy is suspected, immediately discontinue therapy and initiate parenteral thiamine treatment. Monitor until symptoms resolve or improve and thiamine levels normalize. Dose Adjustments Discontinue therapy in patients unable to tolerate 200 mg daily. Consider dose reductions in patients who become transfusion-dependent during therapy with this drug. DOSE MODIFICATIONS WITH CONCOMITANT USE OF STRONG CYP450 3A4 INHIBITORS: Reduce the dose of this drug when administering with strong CYP450 3A4 inhibitors to 200 mg orally once a day. If the strong CYP450 3A4 inhibitor is discontinued, increase the dose of this drug to 300 mg orally once d day during the first 2 weeks after discontinuation of the CYP450 3A4 inhibitor, and then to 400 mg orally once a day thereafter as tolerated. DOSE MODIFICATIONS FOR HEMATOLOGIC ADVERSE REACTIONS: Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with active bleeding: Withhold therapy until resolved to Grade 2 or less or baseline; restart at 100 mg daily below the last given dose. Grade 4 Neutropenia: Withhold therapy until resolved to Grade 2 or less or baseline, restart dose at 100 mg daily below the last given dose. `DOSE MODIFICATIONS FOR NONHEMATOLOGIC ADVERSE REACTIONS: Grade 3 or higher nausea, vomiting, or diarrhea not responding to supportive measures within 48 hours: Withhold therapy until resolved to Grade 1 or less or baseline; restart dose at 100 mg daily below the last given dose. Grade 3 or higher ALT, AST, or bilirubin: Withhold therapy until resolved to Grade 1 or less or baseline; restart dose at 100 mg daily below the last given dose; monitor ALT, AST, and bilirubin (total and direct) more frequently following the dose reduction; if reoccurrence of Grade 3 or higher elevation, discontinue therapy. Grade 3 or higher other nonhematologic toxicities: Withhold therapy until resolved to Grade 1 or less or baseline; restart dose at 100 mg daily below the last given dose. Administration advice: This drug may be taken with or without food. Administration of a high-fat meal may reduce the incidence of nausea and vomiting. If a dose is missed, the next scheduled dose should be taken the following day. Patients taking ruxolitinib before initiation of this drug should taper and discontinue according to the ruxolitinib prescribing information. Side Effects The Most Common nausea vomiting diarrhea constipation tiredness muscle spasms arm, leg, or bone pain headache weight gain dizziness unusual bleeding or bruising fever, chills, cough, painful or frequent urination, or other signs of infection nausea, extreme tiredness, unusual bruising or bleeding, lack of energy, loss of appetite, pain in the upper right part of the stomach, yellowing of the skin or eyes, or flu-like symptoms shortness of breath, fast heartbeat, headache, dizziness, pale skin, confusion, or tiredness pain in the chest, arms, back, neck, jaw, or stomach; breaking out in cold sweat; lightheadedness slow or difficult speech; sudden weakness or numbness of the face, arm or leg; sudden headache; sudden vision problems; sudden difficulty walking swelling, pain, tenderness, warmth or redness in one or both legs shortness of breath, coughing up blood, fast heartbeat, fast breathing, pain when breathing deeply More common Black, tarry stools bleeding gums blood in the urine or stools chills cough fever lower back or side pain painful or difficult urination pale skin pinpoint red spots on the skin sore throat troubled breathing with exertion ulcers, sores, or white spots in the mouth unusual bleeding or bruising unusual tiredness or weakness Bone pain diarrhea dizziness headache lack or loss of strength muscle spasms nausea pain in the arms or legs vomiting weight gain Rare Bladder pain cloudy urine confusion difficult, burning, or painful urination drowsiness frequent urge to urinate lower back or side pain shakiness and unsteady walk trouble remembering uncontrolled eye movements unsteadiness, trembling, or other problems with muscle control or coordination Drug Interactions DRUG INTERACTION Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Fedratinib. Abametapir The serum concentration of Fedratinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Fedratinib can be increased when combined with Abatacept. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Fedratinib. Abrocitinib The serum concentration of Fedratinib can be increased when it is combined with Abrocitinib. Acebutolol The metabolism of Acebutolol can be decreased when combined with Fedratinib. Acenocoumarol The metabolism of Fedratinib can be decreased when combined with Acenocoumarol. Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Fedratinib. Acyclovir The excretion of Acyclovir can be decreased when combined with Fedratinib. Adalimumab The metabolism of Fedratinib can be increased when combined with Adalimumab. Afatinib The serum concentration of Afatinib can be increased when it is combined with Fedratinib. Albendazole The metabolism of Fedratinib can be decreased when combined with Albendazole. Allopurinol Fedratinib may decrease the excretion rate of Allopurinol which could result in a higher serum level. Almotriptan The metabolism of Almotriptan can be decreased when combined with Fedratinib. Alogliptin The metabolism of Alogliptin can be decreased when combined with Fedratinib. Alpelisib The serum concentration of Alpelisib can be increased when it is combined with Fedratinib. Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Fedratinib. Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Fedratinib. Amiodarone The metabolism of Fedratinib can be decreased when combined with Amiodarone. Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Fedratinib. Amoxapine The metabolism of Amoxapine can be decreased when combined with Fedratinib. Amphetamine The metabolism of Amphetamine can be decreased when combined with Fedratinib. Amprenavir The metabolism of Fedratinib can be decreased when combined with Amprenavir. Anakinra The metabolism of Fedratinib can be increased when combined with Anakinra. Antipyrine The metabolism of Antipyrine can be decreased when combined with Fedratinib. Apalutamide The serum concentration of Fedratinib can be increased when it is combined with Apalutamide. Apixaban Fedratinib may decrease the excretion rate of Apixaban which could result in a higher serum level. Apremilast The metabolism of Fedratinib can be increased when combined with Apremilast. Aprepitant The metabolism of Fedratinib can be decreased when combined with Aprepitant. Arformoterol The metabolism of Arformoterol can be decreased when combined with Fedratinib. Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Fedratinib. Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be decreased when combined with Fedratinib. Armodafinil The metabolism of Fedratinib can be decreased when combined with Armodafinil. Arsenic trioxide The serum concentration of Fedratinib can be increased when it is combined with Arsenic trioxide. Artemether The metabolism of Fedratinib can be decreased when combined with Artemether. Artenimol The metabolism of Fedratinib can be decreased when combined with Artenimol. Articaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Articaine. Asciminib The serum concentration of Fedratinib can be increased when it is combined with Asciminib. Astemizole The metabolism of Astemizole can be decreased when combined with Fedratinib. Asunaprevir The serum concentration of Fedratinib can be increased when it is combined with Asunaprevir. Atazanavir The metabolism of Fedratinib can be decreased when combined with Atazanavir. Atenolol The metabolism of Atenolol can be decreased when combined with Fedratinib. Atogepant The serum concentration of Atogepant can be increased when it is combined with Fedratinib. Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Fedratinib. Atorvastatin The excretion of Atorvastatin can be decreased when combined with Fedratinib. Avanafil The serum concentration of Avanafil can be increased when it is combined with Fedratinib. Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Fedratinib. Axitinib The serum concentration of Axitinib can be increased when it is combined with Fedratinib. Azelastine The metabolism of Azelastine can be decreased when combined with Fedratinib. Baricitinib The excretion of Baricitinib can be decreased when combined with Fedratinib. Belantamab The serum concentration of Belantamab mafodotin can be increased when it is combined with Fedratinib. Belinostat The serum concentration of Belinostat can be increased when it is combined with Fedratinib. Belumosudil The serum concentration of Fedratinib can be increased when it is combined with Belumosudil. Belzutifan The metabolism of Belzutifan can be decreased when combined with Fedratinib. Bempedoic acid The excretion of Bempedoic acid can be decreased when combined with Fedratinib. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Fedratinib. Benzatropine The metabolism of Benzatropine can be decreased when combined with Fedratinib. Benzocaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Benzyl alcohol. Benzylpenicillin The excretion of Benzylpenicillin can be decreased when combined with Fedratinib. Bepridil The metabolism of Bepridil can be decreased when combined with Fedratinib. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Fedratinib. Betaxolol The metabolism of Betaxolol can be decreased when combined with Fedratinib. Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Fedratinib. Bimekizumab The metabolism of Fedratinib can be increased when combined with Bimekizumab. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Fedratinib. Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Fedratinib. Boceprevir The metabolism of Fedratinib can be decreased when combined with Boceprevir. Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Fedratinib. Bosentan The excretion of Bosentan can be decreased when combined with Fedratinib. Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Fedratinib. Brentuximab The serum concentration of Brentuximab vedotin can be increased when it is combined with Fedratinib. Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Fedratinib. Brigatinib Fedratinib may decrease the excretion rate of Brigatinib which could result in a higher serum level. Brincidofovir The serum concentration of Brincidofovir can be increased when it is combined with Fedratinib. Bupivacaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Bupivacaine. Buprenorphine The metabolism of Fedratinib can be decreased when combined with Buprenorphine. Buspirone The metabolism of Buspirone can be decreased when combined with Fedratinib. Butacaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Butamben. Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Fedratinib. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Fedratinib. Canagliflozin The serum concentration of Fedratinib can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Fedratinib can be increased when combined with Canakinumab. Cannabidiol The metabolism of Fedratinib can be decreased when combined with Cannabidiol. Capmatinib The serum concentration of Fedratinib can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Capsaicin. Carbamazepine The metabolism of Fedratinib can be increased when combined with Carbamazepine. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Fedratinib. Carfilzomib The serum concentration of Carfilzomib can be increased when it is combined with Fedratinib. Carisoprodol The metabolism of Fedratinib can be decreased when combined with Carisoprodol. Carvedilol The serum concentration of Fedratinib can be increased when it is combined with Carvedilol. Caspofungin The excretion of Caspofungin can be decreased when combined with Fedratinib. Cefradine The excretion of Cefradine can be decreased when combined with Fedratinib. Celecoxib Fedratinib may decrease the excretion rate of Celecoxib which could result in a higher serum level. Celiprolol The metabolism of Celiprolol can be decreased when combined with Fedratinib. Cenobamate The serum concentration of Fedratinib can be decreased when it is combined with Cenobamate. Cephalexin The excretion of Cephalexin can be decreased when combined with Fedratinib. Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Fedratinib. Cerivastatin Fedratinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level. You Might Also Read Pioglitazone; Uses, Contra indications, Dosage, Side Effects, Drug Interactions Certolizumab The metabolism of Fedratinib can be increased when combined with Certolizumab pegol. Cevimeline The metabolism of Cevimeline can be decreased when combined with Fedratinib. Chloramphenicol The metabolism of Fedratinib can be decreased when combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Chloroprocaine. Chloroquine The metabolism of Chloroquine can be decreased when combined with Fedratinib. Chlorpheniramine The metabolism of Chlorpheniramine can be decreased when combined with Fedratinib. Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Fedratinib. Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Fedratinib. Cholecystokinin The excretion of Cholecystokinin can be decreased when combined with Fedratinib. Cholic Acid The excretion of Cholic Acid can be decreased when combined with Fedratinib. Ciclesonide The metabolism of Ciclesonide can be decreased when combined with Fedratinib. Cilostazol The metabolism of Cilostazol can be decreased when combined with Fedratinib. Cimetidine The metabolism of Fedratinib can be decreased when combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Cinchocaine. Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Fedratinib. Ciprofloxacin The metabolism of Fedratinib can be decreased when combined with Ciprofloxacin. Citalopram The metabolism of Fedratinib can be decreased when combined with Citalopram. Cladribine Fedratinib may decrease the excretion rate of Cladribine which could result in a higher serum level. Clarithromycin The metabolism of Fedratinib can be decreased when combined with Clarithromycin. Clevidipine The metabolism of Fedratinib can be decreased when combined with Clevidipine. Clobazam The serum concentration of Clobazam can be increased when it is combined with Fedratinib. Clofarabine Fedratinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clofazimine The serum concentration of Fedratinib can be increased when it is combined with Clofazimine. Clomifene The serum concentration of Clomifene can be increased when it is combined with Fedratinib. Clomipramine The metabolism of Clomipramine can be decreased when combined with Fedratinib. Clonidine The metabolism of Clonidine can be decreased when combined with Fedratinib. Clopidogrel The metabolism of Fedratinib can be decreased when combined with Clopidogrel. Clozapine The metabolism of Fedratinib can be decreased when combined with Clozapine. Cobicistat The metabolism of Fedratinib can be decreased when combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Fedratinib. Cocaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Cocaine. Codeine The metabolism of Codeine can be decreased when combined with Fedratinib. Colchicine The serum concentration of Colchicine can be increased when it is combined with Fedratinib. Conivaptan The metabolism of Fedratinib can be decreased when combined with Conivaptan. Conjugated Fedratinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Fedratinib. Crizotinib The serum concentration of Crizotinib can be increased when it is combined with Fedratinib. Curcumin The metabolism of Fedratinib can be decreased when combined with Curcumin. Cyclophosphamide The metabolism of Fedratinib can be decreased when combined with Cyclophosphamide. Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Fedratinib. Dabigatran etexilate The serum concentration of Dabigatran etexilate can be increased when it is combined with Fedratinib. Dabrafenib The serum concentration of Fedratinib can be decreased when it is combined with Dabrafenib. Daclatasvir The serum concentration of Fedratinib can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Dacomitinib can be increased when it is combined with Fedratinib. Dactinomycin The serum concentration of Dactinomycin can be increased when it is combined with Fedratinib. Danazol The metabolism of Fedratinib can be decreased when combined with Danazol. Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Fedratinib. Daptomycin The serum concentration of Daptomycin can be increased when it is combined with Fedratinib. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fedratinib. Darifenacin The metabolism of Darifenacin can be decreased when combined with Fedratinib. Darolutamide Fedratinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Darunavir The metabolism of Fedratinib can be decreased when combined with Darunavir. Dasabuvir The serum concentration of Dasabuvir can be increased when it is combined with Fedratinib. Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Fedratinib. Daunorubicin Fedratinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Debrisoquine The metabolism of Debrisoquine can be decreased when combined with Fedratinib. Delafloxacin Fedratinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Delavirdine The metabolism of Fedratinib can be decreased when combined with Delavirdine. Desipramine The metabolism of Desipramine can be decreased when combined with Fedratinib. Desvenlafaxine The metabolism of Fedratinib can be decreased when combined with Desvenlafaxine. Deutetrabenazine The metabolism of Deutetrabenazine can be decreased when combined with Fedratinib. Dexamethasone The metabolism of Fedratinib can be increased when combined with Dexamethasone. Dexchlorpheniramine The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Fedratinib. Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Fedratinib. Dexlansoprazole The metabolism of Fedratinib can be decreased when combined with Dexlansoprazole. Dextroamphetamine The metabolism of Dextroamphetamine can be decreased when combined with Fedratinib. Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Fedratinib. Dextropropoxyphene The metabolism of Dextropropoxyphene can be decreased when combined with Fedratinib. Diazepam The metabolism of Fedratinib can be decreased when combined with Diazepam. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Fedratinib. Digoxin Fedratinib may decrease the excretion rate of Digoxin which could result in a higher serum level. Dihydrocodeine The metabolism of Dihydrocodeine can be decreased when combined with Fedratinib. Diltiazem The metabolism of Fedratinib can be decreased when combined with Diltiazem. Dimethyl sulfoxide The metabolism of Fedratinib can be decreased when combined with Dimethyl sulfoxide. Dinoprostone The excretion of Dinoprostone can be decreased when combined with Fedratinib. Diosmin The serum concentration of Fedratinib can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Diphenhydramine. Docetaxel The excretion of Docetaxel can be decreased when combined with Fedratinib. Dolasetron The metabolism of Dolasetron can be decreased when combined with Fedratinib. Dolutegravir Fedratinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. Domperidone The metabolism of Domperidone can be decreased when combined with Fedratinib. Donepezil Fedratinib may decrease the excretion rate of Donepezil which could result in a higher serum level. Dosulepin The metabolism of Dosulepin can be decreased when combined with Fedratinib. Doxazosin The metabolism of Fedratinib can be decreased when combined with Doxazosin. Doxepin The metabolism of Fedratinib can be decreased when combined with Doxepin. Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Fedratinib. Dronabinol The metabolism of Fedratinib can be decreased when combined with Dronabinol. Dronedarone The metabolism of Fedratinib can be decreased when combined with Dronedarone. Duloxetine The metabolism of Duloxetine can be decreased when combined with Fedratinib. Duvelisib Fedratinib may decrease the excretion rate of Duvelisib which could result in a higher serum level. Dyclonine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Dyclonine. Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Fedratinib. Efavirenz The metabolism of Fedratinib can be decreased when combined with Efavirenz. Elagolix The serum concentration of Fedratinib can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Elbasvir can be increased when it is combined with Fedratinib. Eletriptan The metabolism of Eletriptan can be decreased when combined with Fedratinib. Eliglustat The serum concentration of Fedratinib can be increased when it is combined with Eliglustat. Eluxadoline The serum concentration of Eluxadoline can be increased when it is combined with Fedratinib. Elvitegravir The metabolism of Fedratinib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Fedratinib can be increased when combined with Emapalumab. Emtricitabine The excretion of Emtricitabine can be decreased when combined with Fedratinib. Enalapril The excretion of Enalapril can be decreased when combined with Fedratinib. Enasidenib The metabolism of Enasidenib can be decreased when combined with Fedratinib. Encainide The metabolism of Encainide can be decreased when combined with Fedratinib. Encorafenib The metabolism of Encorafenib can be decreased when combined with Fedratinib. Enfortumab The serum concentration of Enfortumab vedotin can be increased when it is combined with Fedratinib. Entrectinib The serum concentration of Fedratinib can be increased when it is combined with Entrectinib. Enzalutamide The serum concentration of Fedratinib can be decreased when it is combined with Enzalutamide. Epinastine The metabolism of Epinastine can be decreased when combined with Fedratinib. Erdafitinib The serum concentration of Fedratinib can be increased when it is combined with Erdafitinib. Ergotamine The metabolism of Fedratinib can be decreased when combined with Ergotamine. Erlotinib The metabolism of Erlotinib can be decreased when combined with Fedratinib. Ertugliflozin Fedratinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. Erythromycin The metabolism of Fedratinib can be decreased when combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fedratinib. Escitalopram The metabolism of Fedratinib can be decreased when combined with Escitalopram. Esketamine The metabolism of Fedratinib can be decreased when combined with Esketamine. Eslicarbazepine The metabolism of Fedratinib can be decreased when combined with Eslicarbazepine. Eslicarbazepine The metabolism of Fedratinib can be decreased when combined with Eslicarbazepine acetate. Esmolol The metabolism of Esmolol can be decreased when combined with Fedratinib. Esomeprazole The metabolism of Fedratinib can be decreased when combined with Esomeprazole. Estradiol The metabolism of Fedratinib can be decreased when combined with Estradiol. Estrone sulfate The excretion of Estrone sulfate can be decreased when combined with Fedratinib. Etanercept The metabolism of Fedratinib can be increased when combined with Etanercept. Ethambutol The metabolism of Fedratinib can be decreased when combined with Ethambutol. Ethanol The metabolism of Fedratinib can be decreased when combined with Ethanol. Ethinylestradiol The metabolism of Fedratinib can be decreased when combined with Ethinylestradiol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Etidocaine. Etoposide The serum concentration of Etoposide can be increased when it is combined with Fedratinib. Etoricoxib The metabolism of Fedratinib can be decreased when combined with Etoricoxib. Etravirine The metabolism of Fedratinib can be decreased when combined with Etravirine. Everolimus The serum concentration of Everolimus can be increased when it is combined with Fedratinib. Ezetimibe Fedratinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Favipiravir The serum concentration of Fedratinib can be increased when it is combined with Favipiravir. Felbamate The metabolism of Fedratinib can be decreased when combined with Felbamate. Fenfluramine The metabolism of Fenfluramine can be decreased when combined with Fedratinib. Fenofibrate The metabolism of Fedratinib can be decreased when combined with Fenofibrate. Fesoterodine The metabolism of Fesoterodine can be decreased when combined with Fedratinib. Fexinidazole The metabolism of Fedratinib can be decreased when combined with Fexinidazole. Fexofenadine The serum concentration of Fexofenadine can be increased when it is combined with Fedratinib. Flecainide The metabolism of Flecainide can be decreased when combined with Fedratinib. Flibanserin The serum concentration of Fedratinib can be increased when it is combined with Flibanserin. Fluconazole The metabolism of Fedratinib can be decreased when combined with Fluconazole. Flunarizine The metabolism of Flunarizine can be decreased when combined with Fedratinib. Fluorouracil Fedratinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. Fluoxetine The metabolism of Fedratinib can be decreased when combined with Fluoxetine. Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Fedratinib. Fluvoxamine The metabolism of Fedratinib can be decreased when combined with Fluvoxamine. Folic acid Fedratinib may decrease the excretion rate of Folic acid which could result in a higher serum level. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Fedratinib. Formoterol The metabolism of Fedratinib can be decreased when combined with Formoterol. Fosnetupitant The metabolism of Fedratinib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Fedratinib can be increased when combined with Fosphenytoin. Fostemsavir Fedratinib may decrease the excretion rate of Fostemsavir which could result in a higher serum level. Fusidic acid The metabolism of Fedratinib can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Futibatinib can be increased when it is combined with Fedratinib. Gadoxetic acid The excretion of Gadoxetic acid can be decreased when combined with Fedratinib. Galantamine The metabolism of Galantamine can be decreased when combined with Fedratinib. Ganciclovir The excretion of Ganciclovir can be decreased when combined with Fedratinib. Gefitinib Fedratinib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Fedratinib. Gemfibrozil The metabolism of Fedratinib can be decreased when combined with Gemfibrozil. Gilteritinib The serum concentration of Gilteritinib can be increased when it is combined with Fedratinib. Glasdegib Fedratinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. Glecaprevir Fedratinib may decrease the excretion rate of Glecaprevir which could result in a higher serum level. Gliclazide The metabolism of Fedratinib can be decreased when combined with Gliclazide. Glyburide Fedratinib may decrease the excretion rate of Glyburide which could result in a higher serum level. Golimumab The metabolism of Fedratinib can be increased when combined with Golimumab. Grazoprevir The serum concentration of Grazoprevir can be increased when it is combined with Fedratinib. Guanidine The excretion of Guanidine can be decreased when combined with Fedratinib. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Fedratinib. Hydrocodone The metabolism of Hydrocodone can be decreased when combined with Fedratinib. Hydroxychloroquine The metabolism of Hydroxychloroquine can be decreased when combined with Fedratinib. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Fedratinib. Idarubicin The metabolism of Idarubicin can be decreased when combined with Fedratinib. Idelalisib Fedratinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. Iloperidone The metabolism of Iloperidone can be decreased when combined with Fedratinib. Imatinib Fedratinib may decrease the excretion rate of Imatinib which could result in a higher serum level. Imipramine The serum concentration of Imipramine can be increased when it is combined with Fedratinib. Indacaterol The serum concentration of Indacaterol can be increased when it is combined with Fedratinib. Indinavir The metabolism of Fedratinib can be decreased when combined with Indinavir. Infliximab The metabolism of Fedratinib can be increased when combined with Infliximab. Inotuzumab The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fedratinib. Ipecac The metabolism of Ipecac can be decreased when combined with Fedratinib. Irinotecan Fedratinib may decrease the excretion rate of Irinotecan which could result in a higher serum level. Isavuconazole The serum concentration of Fedratinib can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Fedratinib can be increased when it is combined with Isavuconazonium. Isoniazid The metabolism of Fedratinib can be decreased when combined with Isoniazid. Isradipine The metabolism of Fedratinib can be decreased when combined with Isradipine. Istradefylline The serum concentration of Fedratinib can be increased when it is combined with Istradefylline. Itraconazole The metabolism of Fedratinib can be decreased when combined with Itraconazole. Ivacaftor The serum concentration of Fedratinib can be increased when it is combined with Ivacaftor. Ivermectin Fedratinib may decrease the excretion rate of Ivermectin which could result in a higher serum level. Ivosidenib The metabolism of Fedratinib can be increased when combined with Ivosidenib. Ixabepilone The serum concentration of Fedratinib can be increased when it is combined with Ixabepilone. Ketoconazole The metabolism of Fedratinib can be decreased when combined with Ketoconazole. Labetalol The metabolism of Fedratinib can be decreased when combined with Labetalol. Lacosamide The metabolism of Fedratinib can be decreased when combined with Lacosamide. Lamivudine Fedratinib may decrease the excretion rate of Lamivudine which could result in a higher serum level. You Might Also Read Which Drugs Are Use For Destroy the Sex? Lansoprazole The metabolism of Fedratinib can be decreased when combined with Lansoprazole. Lapatinib The serum concentration of Fedratinib can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Fedratinib. Lasmiditan The serum concentration of Fedratinib can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Fedratinib. Lefamulin Fedratinib may decrease the excretion rate of Lefamulin which could result in a higher serum level. Leflunomide Fedratinib may decrease the excretion rate of Leflunomide which could result in a higher serum level. Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Fedratinib. Lenvatinib Fedratinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level. Letermovir The metabolism of Fedratinib can be increased when combined with Letermovir. Letrozole The metabolism of Fedratinib can be decreased when combined with Letrozole. Levobetaxolol The metabolism of Levobetaxolol can be decreased when combined with Fedratinib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Levobupivacaine. Levofloxacin The excretion of Levofloxacin can be decreased when combined with Fedratinib. Levoketoconazole The metabolism of Fedratinib can be decreased when combined with Levoketoconazole. Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Fedratinib. Levosalbutamol The excretion of Levosalbutamol can be decreased when combined with Fedratinib. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fedratinib. Lidocaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Lidocaine. Linagliptin The metabolism of Fedratinib can be decreased when combined with Linagliptin. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fedratinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Fedratinib. Lisdexamfetamine The metabolism of Lisdexamfetamine can be decreased when combined with Fedratinib. Lisuride The metabolism of Lisuride can be decreased when combined with Fedratinib. Lofexidine The metabolism of Lofexidine can be decreased when combined with Fedratinib. Lomitapide The serum concentration of Fedratinib can be increased when it is combined with Lomitapide. Lonafarnib The metabolism of Fedratinib can be decreased when combined with Lonafarnib. Loncastuximab The serum concentration of Loncastuximab tesirine can be increased when it is combined with Fedratinib. Loperamide The excretion of Loperamide can be decreased when combined with Fedratinib. Lopinavir The metabolism of Fedratinib can be decreased when combined with Lopinavir. Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Fedratinib. Lorpiprazole The metabolism of Lorpiprazole can be decreased when combined with Fedratinib. Losartan The metabolism of Fedratinib can be decreased when combined with Losartan. Lovastatin The metabolism of Fedratinib can be decreased when combined with Lovastatin. Loxapine The serum concentration of Fedratinib can be increased when it is combined with Loxapine. Luliconazole The serum concentration of Fedratinib can be increased when it is combined with Luliconazole. Lumacaftor The serum concentration of Fedratinib can be decreased when it is combined with Lumacaftor. Lusutrombopag Fedratinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. Lynestrenol The metabolism of Fedratinib can be decreased when combined with Lynestrenol. Manidipine The metabolism of Fedratinib can be decreased when combined with Manidipine. Mannitol The serum concentration of Mannitol can be increased when it is combined with Fedratinib. Maprotiline The metabolism of Maprotiline can be decreased when combined with Fedratinib. Maribavir The serum concentration of Fedratinib can be increased when it is combined with Maribavir. Mavacamten The serum concentration of Fedratinib can be decreased when it is combined with Mavacamten. Meclizine The metabolism of Meclizine can be decreased when combined with Fedratinib. Mefloquine The serum concentration of Fedratinib can be increased when it is combined with Mefloquine. Meloxicam The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Meloxicam. Memantine The metabolism of Fedratinib can be decreased when combined with Memantine. Mephenytoin The metabolism of Fedratinib can be decreased when combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Mepivacaine. Mesoridazine The metabolism of Mesoridazine can be decreased when combined with Fedratinib. Metamfetamine The metabolism of Metamfetamine can be decreased when combined with Fedratinib. Metformin The excretion of Metformin can be decreased when combined with Fedratinib. Methadone The metabolism of Fedratinib can be decreased when combined with Methadone. Methimazole The metabolism of Fedratinib can be decreased when combined with Methimazole. Methotrexate Fedratinib may decrease the excretion rate of Methotrexate which could result in a higher serum level. Methotrimeprazine The metabolism of Methotrimeprazine can be decreased when combined with Fedratinib. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fedratinib. Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Fedratinib. Methsuximide The metabolism of Fedratinib can be decreased when combined with Methsuximide. Methylene blue The serum concentration of Fedratinib can be increased when it is combined with Methylene blue. Methylphenobar The metabolism of Fedratinib can be decreased when combined with Methylphenobarbital. Metoclopramide The metabolism of Metoclopramide can be decreased when combined with Fedratinib. Metoprolol The metabolism of Metoprolol can be decreased when combined with Fedratinib. Metreleptin The metabolism of Fedratinib can be increased when combined with Metreleptin. Mexiletine The metabolism of Mexiletine can be decreased when combined with Fedratinib. Mianserin The metabolism of Mianserin can be decreased when combined with Fedratinib. Miconazole The metabolism of Fedratinib can be decreased when combined with Miconazole. Midostaurin The metabolism of Fedratinib can be decreased when combined with Midostaurin. Mifepristone The serum concentration of Fedratinib can be increased when it is combined with Mifepristone. Milnacipran The metabolism of Fedratinib can be decreased when combined with Milnacipran. Minaprine The metabolism of Minaprine can be decreased when combined with Fedratinib. Mirabegron The serum concentration of Fedratinib can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Fedratinib. Mitapivat The serum concentration of Fedratinib can be increased when it is combined with Mitapivat. Mitotane The metabolism of Fedratinib can be increased when combined with Mitotane. Mitoxantrone Fedratinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. Moclobemide The metabolism of Fedratinib can be decreased when combined with Moclobemide. Modafinil The metabolism of Fedratinib can be decreased when combined with Modafinil. Morphine The serum concentration of Morphine can be increased when it is combined with Fedratinib. Mycophenolate Fedratinib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. Nadolol The metabolism of Nadolol can be decreased when combined with Fedratinib. Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Fedratinib. Naloxone The metabolism of Fedratinib can be decreased when combined with Naloxone. Nateglinide The metabolism of Nateglinide can be decreased when combined with Fedratinib. Nebivolol The metabolism of Fedratinib can be decreased when combined with Nebivolol. Nefazodone The metabolism of Fedratinib can be decreased when combined with Nefazodone. Nelfinavir The metabolism of Fedratinib can be decreased when combined with Nelfinavir. Neratinib The serum concentration of Fedratinib can be increased when it is combined with Neratinib. Netupitant The metabolism of Fedratinib can be decreased when combined with Netupitant. Nevirapine The metabolism of Nevirapine can be decreased when combined with Fedratinib. Nicardipine The metabolism of Fedratinib can be decreased when combined with Nicardipine. Nicergoline The metabolism of Nicergoline can be decreased when combined with Fedratinib. Nifedipine The metabolism of Nifedipine can be decreased when combined with Fedratinib. Nilotinib The metabolism of Fedratinib can be decreased when combined with Nilotinib. Nilutamide The metabolism of Fedratinib can be decreased when combined with Nilutamide. Nilvadipine The metabolism of Fedratinib can be decreased when combined with Nilvadipine. Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Fedratinib. Nitrofurantoin Fedratinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Norgestimate The serum concentration of Fedratinib can be increased when it is combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Fedratinib. Olanzapine The metabolism of Fedratinib can be decreased when combined with Olanzapine. Oliceridine The metabolism of Oliceridine can be decreased when combined with Fedratinib. Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Fedratinib. Ombitasvir Fedratinib may decrease the excretion rate of Ombitasvir which could result in a higher serum level. Omeprazole The metabolism of Fedratinib can be decreased when combined with Omeprazole. Ondansetron The metabolism of Ondansetron can be decreased when combined with Fedratinib. Opium The metabolism of Opium can be decreased when combined with Fedratinib. Oritavancin The metabolism of Fedratinib can be decreased when combined with Oritavancin. Osilodrostat The metabolism of Fedratinib can be decreased when combined with Osilodrostat. Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Fedratinib. Ouabain The excretion of Ouabain can be decreased when combined with Fedratinib. Oxaliplatin Fedratinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Oxcarbazepine The metabolism of Fedratinib can be decreased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Oxetacaine. Oxprenolol The metabolism of Oxprenolol can be decreased when combined with Fedratinib. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Oxybuprocaine. Oxycodone The metabolism of Oxycodone can be decreased when combined with Fedratinib. Oxymorphone The metabolism of Oxymorphone can be decreased when combined with Fedratinib. Ozanimod Fedratinib may decrease the excretion rate of Ozanimod which could result in a higher serum level. Paclitaxel The excretion of Paclitaxel can be decreased when combined with Fedratinib. Pacritinib The serum concentration of Fedratinib can be increased when it is combined with Pacritinib. Palbociclib Fedratinib may decrease the excretion rate of Palbociclib which could result in a higher serum level. Paliperidone The serum concentration of Fedratinib can be increased when it is combined with Paliperidone. Palonosetron The metabolism of Palonosetron can be decreased when combined with Fedratinib. Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Fedratinib. Pantoprazole The metabolism of Fedratinib can be decreased when combined with Pantoprazole. Parathyroid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Fedratinib. Paritaprevir The serum concentration of Paritaprevir can be increased when it is combined with Fedratinib. Paroxetine The metabolism of Fedratinib can be decreased when combined with Paroxetine. Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Fedratinib. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Fedratinib. Penbutolol The metabolism of Penbutolol can be decreased when combined with Fedratinib. Penicillamine The excretion of Penicillamine can be decreased when combined with Fedratinib. Pentamidine The metabolism of Fedratinib can be decreased when combined with Pentamidine. Pentobarbital The metabolism of Fedratinib can be increased when combined with Pentobarbital. Perhexiline The metabolism of Perhexiline can be decreased when combined with Fedratinib. Perphenazine The metabolism of Perphenazine can be decreased when combined with Fedratinib. Phenformin The metabolism of Phenformin can be decreased when combined with Fedratinib. Phenobarbital The metabolism of Fedratinib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Phenol. Phenytoin The metabolism of Fedratinib can be increased when combined with Phenytoin. Pibrentasvir Fedratinib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. Pimozide The metabolism of Pimozide can be decreased when combined with Fedratinib. Pindolol The metabolism of Pindolol can be decreased when combined with Fedratinib. Piperazine The metabolism of Piperazine can be decreased when combined with Fedratinib. Pipotiazine The metabolism of Pipotiazine can be decreased when combined with Fedratinib. Pirfenidone The metabolism of Fedratinib can be decreased when combined with Pirfenidone. Pitavastatin Fedratinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level. Pitolisant The serum concentration of Fedratinib can be decreased when it is combined with Pitolisant. Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Fedratinib. Ponatinib The metabolism of Ponatinib can be decreased when combined with Fedratinib. Posaconazole The metabolism of Fedratinib can be decreased when combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Fedratinib. Potassium The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Fedratinib. Practolol The metabolism of Practolol can be decreased when combined with Fedratinib. Pralatrexate Fedratinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralsetinib The serum concentration of Pralsetinib can be increased when it is combined with Fedratinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Pramocaine. Pravastatin Fedratinib may decrease the excretion rate of Pravastatin which could result in a higher serum level. Praziquantel The metabolism of Fedratinib can be decreased when combined with Praziquantel. Prazosin Fedratinib may decrease the excretion rate of Prazosin which could result in a higher serum level. Prednisolone The serum concentration of Prednisolone phosphate can be increased when it is combined with Fedratinib. Prilocaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Prilocaine. Primaquine The metabolism of Fedratinib can be decreased when combined with Primaquine. Primidone The metabolism of Fedratinib can be increased when combined with Primidone. Procainamide The metabolism of Procainamide can be decreased when combined with Fedratinib. Procaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Procaine. Prochlorperazine The metabolism of Prochlorperazine can be decreased when combined with Fedratinib. Progesterone The metabolism of Fedratinib can be decreased when combined with Progesterone. Proguanil The metabolism of Fedratinib can be decreased when combined with Proguanil. Promazine The metabolism of Promazine can be decreased when combined with Fedratinib. Promethazine The metabolism of Promethazine can be decreased when combined with Fedratinib. Propafenone The serum concentration of Fedratinib can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Propoxycaine. Propranolol The metabolism of Fedratinib can be decreased when combined with Propranolol. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fedratinib. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Fedratinib. Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Fedratinib. Quetiapine The metabolism of Quetiapine can be decreased when combined with Fedratinib. Quinidine The serum concentration of Quinidine can be increased when it is combined with Fedratinib. Quinine The serum concentration of Fedratinib can be increased when it is combined with Quinine. Rabeprazole The metabolism of Fedratinib can be decreased when combined with Rabeprazole. Raloxifene Fedratinib may decrease the excretion rate of Raloxifene which could result in a higher serum level. Ramelteon The metabolism of Fedratinib can be decreased when combined with Ramelteon. Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Fedratinib. Regorafenib The serum concentration of Regorafenib can be increased when it is combined with Fedratinib. Relebactam The excretion of Relebactam can be decreased when combined with Fedratinib. Relugolix The serum concentration of Relugolix can be increased when it is combined with Fedratinib. Remoxipride The metabolism of Remoxipride can be decreased when combined with Fedratinib. Repaglinide The excretion of Repaglinide can be decreased when combined with Fedratinib. Reserpine The serum concentration of Fedratinib can be increased when it is combined with Reserpine. Revefenacin Fedratinib may decrease the excretion rate of Revefenacin which could result in a higher serum level. Ribociclib The metabolism of Fedratinib can be decreased when combined with Ribociclib. Rifabutin The metabolism of Fedratinib can be increased when combined with Rifabutin. Rifampicin The metabolism of Fedratinib can be increased when combined with Rifampicin. Rifamycin The metabolism of Fedratinib can be increased when combined with Rifamycin. Rifapentine The metabolism of Fedratinib can be increased when combined with Rifapentine. Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Fedratinib. Rilonacept The metabolism of Fedratinib can be increased when combined with Rilonacept. Rilpivirine The metabolism of Fedratinib can be decreased when combined with Rilpivirine. Riluzole Fedratinib may decrease the excretion rate of Riluzole which could result in a higher serum level. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Fedratinib. Riociguat Fedratinib may decrease the excretion rate of Riociguat which could result in a higher serum level. Ripretinib Fedratinib may decrease the excretion rate of Ripretinib which could result in a higher serum level. Risperidone The metabolism of Risperidone can be decreased when combined with Fedratinib. Ritonavir The serum concentration of Fedratinib can be increased when it is combined with Ritonavir. Rivaroxaban Fedratinib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rolapitant The serum concentration of Fedratinib can be increased when it is combined with Rolapitant. Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Fedratinib. Ropivacaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Ropivacaine. Rosuvastatin Fedratinib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. Rotigotine The metabolism of Rotigotine can be decreased when combined with Fedratinib. Rucaparib Fedratinib may decrease the excretion rate of Rucaparib which could result in a higher serum level. Rupatadine The metabolism of Rupatadine can be decreased when combined with Fedratinib. Salmon The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Fedratinib. Sapropterin The serum concentration of Fedratinib can be increased when it is combined with Sapropterin. Saquinavir The metabolism of Fedratinib can be decreased when combined with Saquinavir. Sarecycline The serum concentration of Fedratinib can be increased when it is combined with Sarecycline. Satralizumab The serum concentration of Fedratinib can be decreased when it is combined with Satralizumab. Secukinumab The metabolism of Fedratinib can be increased when combined with Secukinumab. Selegiline The metabolism of Selegiline can be decreased when combined with Fedratinib. Selexipag The serum concentration of Selexipag can be increased when it is combined with Fedratinib. Selumetinib Fedratinib may decrease the excretion rate of Selumetinib which could result in a higher serum level. Sertindole The metabolism of Sertindole can be decreased when combined with Fedratinib. Sertraline The metabolism of Fedratinib can be decreased when combined with Sertraline. Sildenafil The serum concentration of Fedratinib can be increased when it is combined with Sildenafil. Silodosin The excretion of Silodosin can be decreased when combined with Fedratinib. Siltuximab The metabolism of Fedratinib can be increased when combined with Siltuximab. Simeprevir The metabolism of Fedratinib can be decreased when combined with Simeprevir. Simvastatin The serum concentration of Fedratinib can be increased when it is combined with Simvastatin. Sincalide The excretion of Sincalide can be decreased when combined with Fedratinib. Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Fedratinib. Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Fedratinib. Sitaxentan The metabolism of Fedratinib can be decreased when combined with Sitaxentan. Sofosbuvir Fedratinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solifenacin The metabolism of Solifenacin can be decreased when combined with Fedratinib. Solriamfetol The excretion of Solriamfetol can be decreased when combined with Fedratinib. Somapacitan The metabolism of Fedratinib can be decreased when combined with Somapacitan. Somatrogon The metabolism of Fedratinib can be increased when combined with Somatrogon. Sorafenib Fedratinib may decrease the excretion rate of Sorafenib which could result in a higher serum level. Sotagliflozin The serum concentration of Fedratinib can be increased when it is combined with Sotagliflozin. Sotalol The metabolism of Sotalol can be decreased when combined with Fedratinib. Sotorasib The serum concentration of Fedratinib can be decreased when it is combined with Sotorasib. St. John’s Wort The metabolism of Fedratinib can be increased when combined with St. John’s Wort. Stiripentol The metabolism of Fedratinib can be decreased when combined with Stiripentol. Sulfasalazine Fedratinib may decrease the excretion rate of Sulfasalazine which could result in a higher serum level. Sumatriptan Fedratinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Suvorexant The serum concentration of Fedratinib can be increased when it is combined with Suvorexant. Tacrolimus The serum concentration of Fedratinib can be increased when it is combined with Tacrolimus. Tafenoquine The metabolism of Tafenoquine can be decreased when combined with Fedratinib. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Fedratinib. Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Fedratinib. Tamsulosin The metabolism of Tamsulosin can be decreased when combined with Fedratinib. Taurocholic acid The excretion of Taurocholic acid can be decreased when combined with Fedratinib. Tazemetostat Fedratinib may decrease the excretion rate of Tazemetostat which could result in a higher serum level. Technetium The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Fedratinib. Technetium The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fedratinib. Tecovirimat The metabolism of Fedratinib can be decreased when combined with Tecovirimat. Tegaserod Fedratinib may decrease the excretion rate of Tegaserod which could result in a higher serum level. Telaprevir The metabolism of Fedratinib can be decreased when combined with Telaprevir. Telithromycin The metabolism of Fedratinib can be decreased when combined with Telithromycin. Telmisartan The metabolism of Fedratinib can be decreased when combined with Telmisartan. Telotristat ethyl The serum concentration of Fedratinib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Fedratinib. Teniposide Fedratinib may decrease the excretion rate of Teniposide which could result in a higher serum level. Tenofovir The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fedratinib. Tenofovir The serum concentration of Tenofovir disoproxil can be increased when it is combined with Fedratinib. Tepotinib The serum concentration of Tepotinib can be increased when it is combined with Fedratinib. Terfenadine The metabolism of Fedratinib can be decreased when combined with Terfenadine. Teriflunomide Fedratinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Fedratinib. Testosterone Fedratinib may decrease the excretion rate of Testosterone which could result in a higher serum level. Testosterone Fedratinib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. Testosterone Fedratinib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. Tetrabenazine The metabolism of Tetrabenazine can be decreased when combined with Fedratinib. Tetracaine The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Tetracaine. Tezacaftor The serum concentration of Tezacaftor can be increased when it is combined with Fedratinib. Theophylline The metabolism of Theophylline can be decreased when combined with Fedratinib. Thiopental The metabolism of Fedratinib can be decreased when combined with Thiopental. Thioridazine The metabolism of Fedratinib can be decreased when combined with Thioridazine. Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fedratinib. Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fedratinib. Ticagrelor The serum concentration of Fedratinib can be increased when it is combined with Ticagrelor. Ticlopidine The metabolism of Fedratinib can be decreased when combined with Ticlopidine. Timolol The metabolism of Timolol can be decreased when combined with Fedratinib. Tiotropium The metabolism of Tiotropium can be decreased when combined with Fedratinib. Tipranavir The metabolism of Fedratinib can be decreased when combined with Tipranavir. Tivozanib The serum concentration of Tivozanib can be increased when it is combined with Fedratinib. Tocilizumab The metabolism of Fedratinib can be increased when combined with Tocilizumab. Tolterodine The metabolism of Tolterodine can be decreased when combined with Fedratinib. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Fedratinib. Topiramate The metabolism of Fedratinib can be decreased when combined with Topiramate. Topotecan The serum concentration of Topotecan can be increased when it is combined with Fedratinib. Torasemide The excretion of Torasemide can be decreased when combined with Fedratinib. Toremifene The serum concentration of Fedratinib can be increased when it is combined with Toremifene. Trabectedin The metabolism of Trabectedin can be decreased when combined with Fedratinib. Tramadol The metabolism of Tramadol can be decreased when combined with Fedratinib. Tranylcypromine The metabolism of Fedratinib can be decreased when combined with Tranylcypromine. You Might Also Read Is Sodium Picosulfate Safe In Pregnancy Trastuzumab The serum concentration of Trastuzumab emtansine can be increased when it is combined with Fedratinib. Trazodone The metabolism of Trazodone can be decreased when combined with Fedratinib. Triclabendazole The metabolism of Fedratinib can be decreased when combined with Triclabendazole. Trilaciclib Fedratinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. Trimethadione The metabolism of Fedratinib can be decreased when combined with Trimethadione. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Fedratinib. Troleandomycin The metabolism of Fedratinib can be decreased when combined with Troleandomycin. Tucatinib Tucatinib may decrease the excretion rate of Fedratinib which could result in a higher serum level. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Fedratinib. Umbralisib The serum concentration of Fedratinib can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Umeclidinium can be increased when it is combined with Fedratinib. Valbenazine The metabolism of Valbenazine can be decreased when combined with Fedratinib. Valproic acid The metabolism of Fedratinib can be decreased when combined with Valproic acid. Valsartan The excretion of Valsartan can be decreased when combined with Fedratinib. Vandetanib The serum concentration of Fedratinib can be increased when it is combined with Vandetanib. Vardenafil The serum concentration of Fedratinib can be increased when it is combined with Vardenafil. Velpatasvir Fedratinib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. Vemurafenib The serum concentration of Fedratinib can be increased when it is combined with Vemurafenib. Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Fedratinib. Venlafaxine The metabolism of Venlafaxine can be decreased when combined with Fedratinib. Verapamil The metabolism of Fedratinib can be decreased when combined with Verapamil. Vernakalant The metabolism of Vernakalant can be decreased when combined with Fedratinib. Vilazodone The metabolism of Fedratinib can be decreased when combined with Vilazodone. Viloxazine The metabolism of Fedratinib can be decreased when combined with Viloxazine. Vinblastine The serum concentration of Vinblastine can be increased when it is combined with Fedratinib. Vincristine The excretion of Vincristine can be decreased when combined with Fedratinib. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Fedratinib. Voclosporin The serum concentration of Fedratinib can be increased when it is combined with Voclosporin. Vonoprazan The metabolism of Fedratinib can be decreased when combined with Vonoprazan. Vorapaxar The serum concentration of Fedratinib can be increased when it is combined with Vorapaxar. Voriconazole The serum concentration of Fedratinib can be increased when it is combined with Voriconazole. Vortioxetine The metabolism of Fedratinib can be decreased when combined with Vortioxetine. Voxelotor The metabolism of Voxelotor can be decreased when combined with Fedratinib. Voxilaprevir Fedratinib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. Yohimbine The metabolism of Yohimbine can be decreased when combined with Fedratinib. Zafirlukast The metabolism of Fedratinib can be decreased when combined with Zafirlukast. Zidovudine Fedratinib may decrease the excretion rate of Zidovudine which could result in a higher serum level. Zimelidine The metabolism of Fedratinib can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Fedratinib can be decreased when combined with Ziprasidone. Zolpidem The metabolism of Fedratinib can be decreased when combined with Zolpidem. Zonisamide The serum concentration of Fedratinib can be increased when it is combined with Zonisamide. Zuclopenthixol The metabolism of Zuclopenthixol can be decreased when combined with Fedratinib. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy This drug should be used during pregnancy only if the benefit outweighs the risk. Adequate methods of contraception should be encouraged. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Lactation A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Data not available Because of the potential for serious adverse reactions in a breastfed child, advise patients not to breastfeed during therapy and for at least 1 month after. How should this medicine be used? Fedratinib comes as a capsule to take by mouth. It is usually taken once a day, with or without food. Taking fedratinib with a high fat meal may help to reduce nausea and vomiting. Take fedratinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take fedratinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Your doctor will order blood tests before and during your treatment to see how you are affected by this medication. Your doctor may increase or decrease your dose of fedratinib during your treatment, or may tell you to stop taking fedratinib temporarily or permanently. This depends on how well the medication works for you, your lab test results, and if you experience side effects. Talk to your doctor about how you are feeling during your treatment. Other uses for this medicine This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before taking fedratinib, tell your doctor and pharmacist if you are allergic to fedratinib, any other medications, or any of the ingredients in fedratinib capsules. Ask your pharmacist or check the Medication Guide for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin (Biaxin, in PrevPac), diltiazem (Cardizem, Dilacor, Tiazac, others), erythromycin (E.E.S., E-mycin, Erythrocin), idelalisib (Zydelig), indinavir (Crixivan), itraconazole (Sporanox), ketoconazole (Nizoral), metoprolol (Lopressor, Toprol XL, in Dutoprol, others), midazolam (Versed), nefazodone, nelfinavir (Viracept), omeprazole (Prilosec, in Zegerid), pantoprazole (Protonix), ribociclib (Kisqali, Kisqali, in Femera), ritonavir (Norvir), ruxolitinib (Jakafi), and saquinavir (Invirase). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with fedratinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor if you if you smoke or if you have ever smoked. Also tell your doctor if you have or have ever had cancer, pancreatitis (swelling of the pancreas), blood clots, a stroke, a heart attack or other heart problems, liver or kidney disease. tell your doctor if you are pregnant or plan to become pregnant. If you become pregnant while taking fedratinib, call your doctor. do not breastfeed during your treatment with fedratinib and for at least 1 month after your final dose. if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking fedratinib. References https://www.cancer.gov/about-cancer/treatment/drugs/fedratinibhydrochloride https://www.drugs.com/mtm/fedratinib.html https://medlineplus.gov/druginfo/meds/a619058.html https://go.drugbank.com/drugs/DB12500 https://en.wikipedia.org/wiki/Fedratinib https://www.mayoclinic.org/drugs-supplements/fedratinib-oral-route/side-effects/drg-20469997https://www.mayoclinic.org/drugs-supplements/fedratinib-oral-route/side-effects/drg-20469997 https://pubchem.ncbi.nlm.nih.gov/compound/Fedratinib https://pubchem.ncbi.nlm.nih.gov/compound/Fedratinib-dihydrochloride-monohydrate https://www.webmd.com/drugs/2/drug-177751/fedratinib-oral/details/list-sideeffects ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Fedratinib [USAN:INN] https://chem.nlm.nih.gov/chemidplus/sid/0936091268 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ DrugBank https://www.drugbank.ca/legal/terms_of_use Fedratinib https://www.drugbank.ca/drugs/DB12500 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Fedratinib https://comptox.epa.gov/dashboard/DTXSID90239483 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice Fedratinib https://echa.europa.eu/information-on-chemicals Fedratinib https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/273390 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking FEDRATINIB https://gsrs.ncats.nih.gov/ginas/app/beta/substances/6L1XP550I6 ChEBI http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:91408 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Fedratinib https://www.ncbi.nlm.nih.gov/books/n/livertox/Fedratinib/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C88293 NCI Thesaurus Tree https://ncit.nci.nih.gov ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1287853/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Chemical Probes Portal Fedratinib https://www.chemicalprobes.org/fedratinib Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp fedratinib https://ctdbase.org/detail.go?type=chem&acc=C528327 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads FEDRATINIB https://www.dgidb.org/drugs/FEDRATINIB IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license fedratinib https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Fedratinib http://idrblab.net/ttd/data/drug/details/D0G8BM ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ Nature Chemical Biology https://pubchem.ncbi.nlm.nih.gov/substance/172131313 European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Inrebic (EMEA/H/C/005026) https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ FDA Medication Guides https://www.fda.gov/about-fda/about-website/website-policies#linking Inrebic https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Fedratinib http://www.hmdb.ca/metabolites/HMDB0247668 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Fedratinib Hydrochloride https://www.cancer.gov/about-cancer/treatment/drugs/fedratinibhydrochloride NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html fedratinib https://rxnav.nlm.nih.gov/id/rxnorm/2197490 Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2TA PubChem https://pubchem.ncbi.nlm.nih.gov RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=37054073-795242371 Thieme Chemistry https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=37054073-795242371 Wikidata https://creativecommons.org/publicdomain/zero/1.0/ Fedratinib https://www.wikidata.org/wiki/Q7670147 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Fedratinib https://www.ncbi.nlm.nih.gov/mesh/67528327 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html KEGG https://www.kegg.jp/kegg/legal.html Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html NORMAN Suspect List Exchange https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking FDA Drug Type and Pharmacologic Classification https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory PATENTSCOPE (WIPO) SID 391188859 https://pubchem.ncbi.nlm.nih.gov/substance/391188859 Show More